EP2941250A4 - Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent - Google Patents

Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent

Info

Publication number
EP2941250A4
EP2941250A4 EP13840277.1A EP13840277A EP2941250A4 EP 2941250 A4 EP2941250 A4 EP 2941250A4 EP 13840277 A EP13840277 A EP 13840277A EP 2941250 A4 EP2941250 A4 EP 2941250A4
Authority
EP
European Patent Office
Prior art keywords
ppi
patients
combination
immune tolerance
insulin independence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13840277.1A
Other languages
German (de)
French (fr)
Other versions
EP2941250A1 (en
Inventor
Claresa Levetan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US2013/061972 external-priority patent/WO2014052625A1/en
Publication of EP2941250A1 publication Critical patent/EP2941250A1/en
Publication of EP2941250A4 publication Critical patent/EP2941250A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP13840277.1A 2013-01-04 2013-09-26 Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent Withdrawn EP2941250A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361749197P 2013-01-04 2013-01-04
PCT/US2013/061972 WO2014052625A1 (en) 2012-09-27 2013-09-26 Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent

Publications (2)

Publication Number Publication Date
EP2941250A1 EP2941250A1 (en) 2015-11-11
EP2941250A4 true EP2941250A4 (en) 2016-07-27

Family

ID=54250581

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13840277.1A Withdrawn EP2941250A4 (en) 2013-01-04 2013-09-26 Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent

Country Status (2)

Country Link
EP (1) EP2941250A4 (en)
JP (1) JP2016503070A (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8732150B2 (en) 2010-09-23 2014-05-20 Salesforce.Com, Inc. Methods and apparatus for suppressing network feed activities using an information feed in an on-demand database service environment
US9529488B2 (en) 2013-03-15 2016-12-27 Salesforce.Com, Inc. Systems and methods for creating custom actions
US9665261B2 (en) 2013-10-28 2017-05-30 Salesforce.Com, Inc. Providing a user interface for customizing state transitions of panes in a bounding window
US10198484B2 (en) 2015-09-10 2019-02-05 Salesforce.Com, Inc. Displaying reduced and detailed visual representations of calendar items based on mouse cursor movement
JP2019077615A (en) * 2016-03-09 2019-05-23 公立大学法人和歌山県立医科大学 Therapeutic agents for non-alcoholic fatty liver diseases/non-alcoholic steatohepatitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128083A2 (en) * 2005-05-25 2006-11-30 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128083A2 (en) * 2005-05-25 2006-11-30 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOJ-CARCELLER DIANA: "Proton pump inhibitors: impact on glucose metabolism", ENDOCRINE, vol. 43, no. 1, 12 August 2012 (2012-08-12), pages 22 - 32, XP002758860 *
LEVETAN C: "Distinctions between islet neogenesis and [beta]-cell replication: Implications for reversal of Type 1 and 2 diabetes", JOURNAL OF DIABETES 2010 WILEY-BLACKWELL AUS, vol. 2, no. 2, June 2010 (2010-06-01), pages 76 - 84, XP002758861, ISSN: 1753-0393 *
See also references of WO2014052625A1 *

Also Published As

Publication number Publication date
EP2941250A1 (en) 2015-11-11
JP2016503070A (en) 2016-02-01

Similar Documents

Publication Publication Date Title
HK1226007A1 (en) Disposable delivery assembly for a drug delivery device
HK1221137A1 (en) Diabetes management system with a medical device
HK1218580A1 (en) Insulin time action model
HK1219631A1 (en) Discretionary insulin delivery systems and methods
HK1223579A1 (en) Drug infusion device with safety interlock
HRP20190557T1 (en) Insulin glargine/lixisenatide fixed ratio formulation
HK1199414A1 (en) Medicament delivery device with needle assembly removal mechanism
EP2974762A4 (en) Syringe assembly, syringe assembly packaging, and pre-filled syringe
EP3006066A4 (en) Syringe and prefilled syringe
HK1224236A1 (en) Medicine injection device with a pain-reduction member
EP2982401A4 (en) Drug injection syringe
HK1222351A1 (en) Drive assembly for a drug delivery device and drug delivery device comprising a drive assembly
HK1222145A1 (en) Drive assembly for a drug delivery device and drug delivery device comprising a drive assembly
HK1217003A1 (en) Drive assembly for a drug delivery device and drug delivery device
HK1225664A1 (en) Assembly for a drug delivery device and drug delivery device
IL237597A0 (en) Nutritional composition for pregnant women with a beneficial glucose and insulin profile
HK1215551A1 (en) Assembly for a drug delivery device and drug delivery device
HK1223529A1 (en) Low glucose treatment for people with diabetes
HK1225673A1 (en) Assembly for a drug delivery device and drug delivery device
EP3071256A4 (en) Medical device with safety features
EP2941250A4 (en) Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
EP3038675A4 (en) Syringe with integral ampule
HK1217004A1 (en) Assembly for a drug delivery device and drug delivery device
HK1213510A1 (en) Assembly for a drug delivery device and drug delivery device with such an assembly
IL244225A0 (en) Assembly for a drug delivery device and drug delivery device

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160629

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/39 20150101ALI20160621BHEP

Ipc: A61K 31/415 20060101ALI20160621BHEP

Ipc: A61P 3/08 20060101ALI20160621BHEP

Ipc: A61P 3/10 20060101ALI20160621BHEP

Ipc: A61K 38/17 20060101ALI20160621BHEP

Ipc: A61K 9/20 20060101ALI20160621BHEP

Ipc: A61K 31/4439 20060101ALI20160621BHEP

Ipc: C12N 5/071 20100101ALI20160621BHEP

Ipc: A61K 31/44 20060101AFI20160621BHEP

Ipc: A61K 9/48 20060101ALI20160621BHEP

Ipc: A61K 38/13 20060101ALI20160621BHEP

Ipc: A61K 45/06 20060101ALI20160621BHEP

17Q First examination report despatched

Effective date: 20170619

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180103